This workgroup is convened for bi-directional discussions between CDC/APHL/CSTE regarding increasing use of serology during the COVID-19 response. This group will discuss issues around the interpretation of serology results and the utility for understanding disease burden. This group will also discuss different sero-prevalence approaches, challenges, and developed protocols that may serve as resources for other jurisdictions implementing sero-prevalence studies.
